Corvus Pharmaceuticals (CRVS) Other Operating Expenses (2015 - 2026)

Corvus Pharmaceuticals' Other Operating Expenses history runs 6 years deep, the most recent figure standing at $4.2 million for Q1 2026.

• On a quarterly basis, Other Operating Expenses rose 544.82% year-over-year to $4.2 million in Q1 2026; TTM through Mar 2026 was $2.7 million, a 220.68% increase from a year earlier, with the FY2022 full-year figure at $22000.0, changed N/A from the prior year.
• Other Operating Expenses grew to $4.2 million in Q1 2026 per CRVS's latest filing, from -$617000.0 in the prior quarter.
• Across five years, Other Operating Expenses topped out at $4.2 million in Q1 2026 and bottomed at -$946000.0 in Q1 2025.
• The 3-year median for Other Operating Expenses is -$617000.0 (2025), against an average of $412285.7.
• Across the five-year window, Other Operating Expenses sank 139.16% in 2025 and surged 544.82% in 2026, its largest moves.
• Year by year, Other Operating Expenses stood at -$776000.0 in 2024, then advanced by 20.49% to -$617000.0 in 2025, then jumped by 782.01% to $4.2 million in 2026.
• Per Business Quant, the three latest CRVS Other Operating Expenses figures stand at $4.2 million (Q1 2026), -$617000.0 (Q3 2025), and -$848000.0 (Q2 2025).